Mayo Clinic teams with Ivy Foundation to study brain tumor vaccines
The Ben & Catherine Ivy Foundation (Ivy Foundation) announced a gift of nearly $1.2 million to study brain tumor vaccines that combine a patient’s immune stimulators with tumor cultures from other patients.
The Ivy Foundation selected the study led by Allan B. Dietz, Ph.D., head of Mayo Clinic’s Human Cellular Therapy Laboratory, and Ian Parney, M.D. Ph.D., a neurosurgeon and immunobiologist, because of Dr. Dietz’s track record in brain cancer research, among other things.
“Mayo Clinic was selected as one of our brain cancer research partners because of the merit of the historical research done by Dr. Dietz and their ability to execute the project,” said Catherine Ivy, founder and president of the Ivy Foundation. “We believe this creative project will contribute important information to brain cancer research.”
The study will combine a patient’s optimized dendritic cells, known to be potent immune stimulators, with pooled and well-characterized cellular debris – known as lysates – from other patients’ brain tumor cultures to generate a tumor vaccine.
“We are combining this new approach with new methods for monitoring and tracking changes in the immune system,” said Dr. Dietz. “Together, we believe that this approach will allow us to identify and treat those patients most likely to benefit from this therapy.”
The Ivy Foundation has a research funding focus on glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adults, and is the largest privately funded brain cancer research foundation in North America.
“We are extremely grateful for the Ivy Foundation’s support for our brain tumor vaccine clinical trial,” said Dr. Parney. “Their help has been crucial to bringing this promising new experimental treatment to patients diagnosed with glioblastoma. With their assistance, we hope to improve the outlook for patients with this highly aggressive brain cancer.”